

October 16, 2026

Details Two Class Actions Lawsuit 2026

HCTN has become aware of two class actions lawsuits available to self-funded employers.

- 1) The **Generic Pharmaceuticals Pricing Antitrust Litigation (End-Payer Class Action Settlement)** stems from extensive multi-district litigation (*In re Generic Pharmaceuticals Pricing Antitrust Litigation*) alleging widespread anticompetitive behavior across the generic pharmaceutical industry. According to the lawsuits, these anticompetitive practices artificially inflated the costs of hundreds of common generic medications (including treatments for high blood pressure, cholesterol, diabetes, asthma, depression, and infections) by up to 1,000% or more in some instances. The **End-Payer Class (EPP)** has secured settlements totaling **approximately \$533 million**. The class period generally applies to purchases made between **May 1, 2009, and December 31, 2019** (slight variations depending on the specific drug and settlement). **Deadline to submit claims for this period is Nov 9, 2026**. The Attorney General of TN is part of a separate consumer reconstitution action with a March 8, 2027 deadline.
- 2) The **third-party payer (TPP) opioid** class action litigation represents a major segment of the broader multidistrict litigation (*In re National Prescription Opiate Litigation*, in the U.S. District Court for the Northern District of Ohio). The class action lawsuit alleged that pharmaceutical manufacturers, wholesale distributors, and retail pharmacy chains engaged in deceptive marketing, oversupplying, and improper distribution of prescription opioids. As a consequence, third-party payers were forced to cover hundreds of millions of dollars in illegitimate or overprescribed opioid prescriptions, alongside secondary healthcare costs such as addiction treatment, emergency care, inpatient hospitalization, and overdose interventions. Reached in mid-2024, the three largest U.S. pharmaceutical distributors agreed to establish a **\$300 million settlement fund** specifically dedicated to private and commercial third-party payers. To participate in the settlement recovery funds, third-party payers must show that they paid or incurred costs between **January 1, 1996, and mid-2026** for:
 - **Prescription Claims:** Direct coverage or reimbursement of branded or generic prescription opioids.
 - **Treatment & Abatement Claims:** Medical claims for substance use disorder (SUD) treatment, addiction recovery, inpatient detox, Naloxone/Narcan administration, or emergency care related to opioid misuse or overdose.

The primary deadline for Third-Party Payers (TPPs) to submit a claim in the active opioid class action settlement is **December 1, 2026**.

See contact info for DCAP Claims, a third party recovery firm.

Jordan Harmony, Sr Operations Advisor
DCAP Claims
702-588-4645
jharmony@dcapclaims.com